𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors

✍ Scribed by Mariano Provencio; Rosario García-Campelo; Dolores Isla; Javier de Castro

Book ID
107596533
Publisher
Springer Milan
Year
2009
Tongue
Spanish
Weight
397 KB
Volume
11
Category
Article
ISSN
1699-048X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Molecular monitoring in chronic myeloid
Molecular monitoring in chronic myeloid leukemia : Response to tyrosine kinase inhibitors and prognostic implications
✍ Elias Jabbour; Jorge E. Cortes; Hagop M. Kantarjian 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

## Abstract The majority of patients with chronic‐phase (CP) chronic myeloid leukemia (CML) who are treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve cytogenetic disease remission (ie, Philadelphia chromosome‐positive cells undetectable by cytogenetic evaluation